Rallybio Corporation — Q2 2023 Form 10-Q Summary
Business context and reporting period
Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases. Its two clinical-stage programs are RLYB212, an anti-HPA-1a antibody for prevention of fetal and neonatal alloimmune thrombocytopenia, and RLYB116, a C5 complement inhibitor. RLYB114, RLYB331 and additional metabolic and rare-disease programs remain in earlier development stages. The filing covers the three and six months ended June 30, 2023, and was filed August 8, 2023.
The company has no approved products and has never generated revenue from product commercialization.
Key financial metrics
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $13.1 million | $24.3 million |
| General and administrative expense | $7.0 million | $14.1 million |
| Total operating expenses | $20.1 million | $38.5 million |
| Interest and other income, net | $1.7 million | $3.3 million |
| Loss on investment in joint venture | $0.2 million | $0.8 million |
| Net loss | $18.6 million | $35.9 million |
| Basic and diluted loss per share | $0.46 | $0.89 |
| Net cash used in operating activities | Not separately provided | $32.1 million |
There is no meaningful revenue or operating margin to report because Rallybio remains pre-commercial and loss-making. The accumulated deficit was $196.6 million at June 30, 2023.
- Cash and cash equivalents: $32.6 million.
- Marketable securities: $105.3 million.
- Total cash, cash equivalents and marketable securities: $137.8 million.
- Total assets: $147.6 million; total liabilities: $8.3 million; stockholders’ equity: $139.3 million.
- The company had no debt financing or credit facility disclosed; liabilities primarily consisted of accounts payable, accrued expenses and operating lease liabilities.
- Cash used in investing activities was $7.7 million of net inflow, principally reflecting $70.0 million of marketable-security maturities against $61.6 million of purchases.
- Cash provided by financing activities was $0.1 million, primarily from the employee stock purchase plan, net of offering costs.
Material changes versus the prior comparable period
- Second-quarter research and development expense increased $3.0 million, or approximately 30%, to $13.1 million, driven primarily by higher RLYB212 clinical development and manufacturing costs and higher RLYB116 development costs.
- Six-month research and development expense increased $6.5 million, or approximately 37%, to $24.3 million. RLYB212 spending increased $7.0 million and RLYB116 spending increased $2.2 million.
- General and administrative expense declined $0.5 million in the second quarter and was essentially unchanged for the six-month period.
- Interest and other income increased substantially because of higher yields and interest income on marketable securities: $1.7 million versus $0.4 million in the second quarter and $3.3 million versus $0.6 million for the six-month period.
- Net loss increased $1.0 million in the second quarter and $3.9 million for the six-month period, despite the increase in interest income, primarily because of higher development spending.
- Operating cash usage increased from $27.3 million to $32.1 million for the six-month period.
- Cash and marketable securities declined from $169.0 million at December 31, 2022 to $137.8 million at June 30, 2023.
- RLYB331 generated $3.1 million of asset-acquisition in-process research and development expense in the second quarter of 2022; no comparable charge was recorded in 2023.
Guidance, outlook, commentary and risks
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital requirements into the first quarter of 2025, although the filing cautions that the estimate could prove incorrect and resources could be exhausted sooner.
- The financial statements state that liquidity is expected to be sufficient for more than 12 months from issuance, but the company will require substantial additional capital to fund development through regulatory approval and commercialization.
- Management implemented cash-preservation initiatives, including reviewing discretionary expenses and managing the timing of certain preclinical activities.
- RLYB212 achieved proof-of-concept in a Phase 1b study. The company expected to report multiple-dose Phase 1 results in the fourth quarter of 2023, complete comprehensive toxicology in the fourth quarter of 2023, and initiate a Phase 2 dose-confirmation study in the second half of 2024.
- The FNAIT natural-history study planned to screen approximately 7,600 women by year-end 2023, with an overall target of up to 30,000 expectant mothers.
- Initial Phase 1 data for RLYB116 was expected in the fourth quarter of 2023, with intended disclosure of the initial target indications at that time.
- On August 1, 2023, Stephen Uden became Chief Executive Officer and remained President; Martin Mackay became Executive Chairman.
- Principal risks include continued losses, dependence on RLYB212 and RLYB116, need for additional financing, clinical and regulatory failure, patient-enrollment challenges in rare diseases, reliance on contract research and manufacturing organizations, potential companion-diagnostic requirements, competition, intellectual-property disputes, and uncertain reimbursement and market acceptance.
- The company had a 50% interest in a joint venture, with no remaining carrying value at June 30, 2023. It funded the joint venture approximately $0.8 million during the first six months and an additional $0.8 million after quarter-end through the financial-statement issuance date.
- No material litigation was pending according to management, and no off-balance-sheet arrangements were reported.
- Disclosure controls and procedures were assessed as effective as of June 30, 2023, with no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Liquidity runway: Reconcile the stated runway through the first quarter of 2025 with the $32.1 million six-month operating cash burn and planned clinical-development spending.
- Capital needs and dilution: Assess the likelihood and timing of additional equity, debt or partnership financing. The company had an unused $100 million at-the-market facility and approximately 3.3 million outstanding pre-funded warrant shares.
- RLYB212 execution: Verify completion of toxicology work, Phase 1 multiple-dose results, regulatory interactions and the expected timing and design of the Phase 2 study.
- RLYB116 development: Verify Phase 1 safety, pharmacokinetic and pharmacodynamic data and the selected indications.
- Clinical and regulatory risk: Determine whether early proof-of-concept data translate into efficacy and safety in pregnant patients and larger registrational studies, and whether regulators require a companion diagnostic.
- Cash-burn composition: Track the growth of program-specific R&D costs, manufacturing commitments, share-based compensation and joint-venture funding.
- Ownership and overhang: Consider potential dilution from equity compensation, pre-funded warrants, registration rights and the company’s at-the-market program.